Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within hepatocytes, which limits its access to the circulation and exposes the lungs to protease-mediated tissue damage.
Coherus plans Humira biosimilar sale at 85% discount – Pharmaceutical Technology
Humira was AbbVie’s blockbuster drug with sales of $21.2bn in 2022. Credit: Coherus BioSciences. Coherus BioSciences has signed a US national distribution agreement with speciality